Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (21)

2024

  1. ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression

    International Journal of Molecular Sciences, Vol. 25, Núm. 6

2022

  1. ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology

    Cancers, Vol. 14, Núm. 14

  2. Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

    Biomolecules, Vol. 12, Núm. 11

  3. Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

    Therapeutic Advances in Medical Oncology, Vol. 14

  4. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

    Cancer research, Vol. 82, Núm. 24, pp. 4670-4679

2021

  1. Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer

    npj Precision Oncology, Vol. 5, Núm. 1

  2. Genomic mapping of splicing-related genes identify amplifications in lsm1, clns1a, and ilf2 in luminal breast cancer

    Cancers, Vol. 13, Núm. 16

  3. MZ1 co-operates with trastuzumab in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  4. Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation

    International Journal of Molecular Sciences, Vol. 22, Núm. 8

2020

  1. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

    Breast Cancer Research, Vol. 22, Núm. 1

  2. Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis

    Molecular Diagnosis and Therapy, Vol. 24, Núm. 2, pp. 143-151

  3. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127

  4. Proteolysis targeting chimeras (PROTACs) in cancer therapy

    Journal of Experimental and Clinical Cancer Research, Vol. 39, Núm. 1

2019

  1. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

  2. Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome

    OncoImmunology, Vol. 8, Núm. 10

  3. Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis

    Frontiers in Oncology, Vol. 9

  4. Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis

    Cancer Treatment Reviews, Vol. 77, pp. 11-19

  5. TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells

    Cancer Letters, Vol. 453, pp. 34-44

2018

  1. Refining Early Antitumoral Drug Development

    Trends in Pharmacological Sciences

2017

  1. Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications

    Molecular Oncology, Vol. 11, Núm. 12, pp. 1788-1805